Yi-Ze Li1, Wei-Ning Liang1, Guo-Wei Zhang2, Zhi-Qiang Weng3, Yong Zhong3, Song Xu4, Xue-Jun Shang1. 1. Department of Andrology, Jinling Hospital Affiliated to Southern Medical University / General Hospital of Eastern Theater Command, Nanjing, Jiangsu 210002, China. 2. Department of Urology, Suqian First People's Hospital, Suqian, Jiangsu 223800, China. 3. Department of Outpatients, Jinling Hospital Affiliated to Southern Medical University / General Hospital of Eastern Theater Command, Nanjing, Jiangsu 210002, China. 4. Department of Urology, Jinling Hospital Affiliated to Southern Medical University / General Hospital of Eastern Theater Command, Nanjing, Jiangsu 210002, China.
Abstract
OBJECTIVE: To investigate the efficacy and safety of lycopene in the treatment of BPH with lower urinary tract symptoms (LUTS). METHODS: Totally, 127 BPH patients with LUTS were treated with oral lycopene tablets at 500 mg bid in the Department of Andrology of Jinling Hospital from January 2018 to January 2019. At 8 and 16 weeks of medication, we compared the IPSS, quality of life (QOL) score, prostate volume, PSA level, maximum urinary flow rate (Qmax), postvoid residual urine volume (PVR) and the incidence of adverse reactions before and after treatment. RESULTS: A total of 120 patients completed the treatment. Compared with the baseline, significant improvement was observed after 8 weeks of medication in the IPSS (［18.42 ± 4.59］ vs ［14.13 ± 4.51］, P < 0.01) and QOL score (［4.34 ± 1.37］ vs ［3.14 ± 1.25］, P < 0.01), and even more significant at 16 weeks in the IPSS (［18.42 ± 4.59］ vs ［10.29 ± 3.61］, P< 0.01), QOL score (［4.34 ± 1.37］ vs ［2.17 ± 1.35］, P < 0.01), PSA (［3.87 ± 3.14］ vs ［2.90 ± 3.07］ μg/L, P < 0.01), Qmax (［10.62 ± 2.08］ vs ［14.15 ± 3.66］ ml/s, P < 0.01) and PVR (［35.88 ± 15.33］ vs ［18.36 ± 13.09］ ml, P < 0.01), but there was no statistically significant difference in the prostate volume before and after treatment (［39.85 ± 10.22］ vs ［38.16 ± 10.12］ ml, P > 0.05), and no adverse reactions in any of the patients. CONCLUSIONS: Lycopene has a good therapeutic effect on BPH with LUTS, which can significantly improve the patients' quality of life without causing adverse reactions.
OBJECTIVE: To investigate the efficacy and safety of lycopene in the treatment of BPH with lower urinary tract symptoms (LUTS). METHODS: Totally, 127 BPH patients with LUTS were treated with oral lycopene tablets at 500 mg bid in the Department of Andrology of Jinling Hospital from January 2018 to January 2019. At 8 and 16 weeks of medication, we compared the IPSS, quality of life (QOL) score, prostate volume, PSA level, maximum urinary flow rate (Qmax), postvoid residual urine volume (PVR) and the incidence of adverse reactions before and after treatment. RESULTS: A total of 120 patients completed the treatment. Compared with the baseline, significant improvement was observed after 8 weeks of medication in the IPSS (［18.42 ± 4.59］ vs ［14.13 ± 4.51］, P < 0.01) and QOL score (［4.34 ± 1.37］ vs ［3.14 ± 1.25］, P < 0.01), and even more significant at 16 weeks in the IPSS (［18.42 ± 4.59］ vs ［10.29 ± 3.61］, P< 0.01), QOL score (［4.34 ± 1.37］ vs ［2.17 ± 1.35］, P < 0.01), PSA (［3.87 ± 3.14］ vs ［2.90 ± 3.07］ μg/L, P < 0.01), Qmax (［10.62 ± 2.08］ vs ［14.15 ± 3.66］ ml/s, P < 0.01) and PVR (［35.88 ± 15.33］ vs ［18.36 ± 13.09］ ml, P < 0.01), but there was no statistically significant difference in the prostate volume before and after treatment (［39.85 ± 10.22］ vs ［38.16 ± 10.12］ ml, P > 0.05), and no adverse reactions in any of the patients. CONCLUSIONS: Lycopene has a good therapeutic effect on BPH with LUTS, which can significantly improve the patients' quality of life without causing adverse reactions.
Authors: Piotr Kutwin; Piotr Falkowski; Roman Łowicki; Magdalena Borowiecka-Kutwin; Tomasz Konecki Journal: Nutrients Date: 2022-02-18 Impact factor: 5.717